Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ipsen SA (IPN)
Ipsen SA stock price live, this page displays EPA IPN stock exchange data. View the IPN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ipsen SA real time stock price chart below.
What Is the Ipsen SA Stock Price Today?
The Ipsen SA stock price today is 100.70.
What Is the Stock Symbol for Ipsen SA?
The stock ticker symbol for Ipsen SA is IPN.
Is IPN the Same as $IPN?
$IPN is a common way to refer to the Ipsen SA ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Paris stock exchange.
Is Ipsen SA a Good Stock to Buy?
Determining whether Ipsen SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Ipsen SA share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPN quote. (ISIN: FR0010259150)
What Is the Ipsen SA Stock Price Today?
The Ipsen SA stock price today is 100.70.
What Is the Stock Symbol for Ipsen SA?
The stock ticker symbol for Ipsen SA is IPN.
Is IPN the Same as $IPN?
$IPN is a common way to refer to the Ipsen SA ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Paris stock exchange.
Is Ipsen SA a Good Stock to Buy?
Determining whether Ipsen SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Ipsen SA share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPN quote. (ISIN: FR0010259150)
100.70
-1.00(-0.98%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
100.70
102.30
52 wk Range
88.30
125.40
IPN Scorecard
Full Analysis
Net income is expected to grow this year
IPN is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
100.70102.30
52 wk Range
88.30125.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.39%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.39%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
IPN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Ipsen SA Company Profile
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Compare IPN to Peers and Sector
Metrics to compare | IPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.6x | 20.6x | −0.4x | |
PEG Ratio | −0.51 | 0.09 | 0.00 | |
Price / Book | 2.0x | 3.6x | 2.6x | |
Price / LTM Sales | 2.3x | 2.6x | 2.9x | |
Upside (Analyst Target) | - | 9.9% | 51.7% | |
Fair Value Upside | Unlock | 18.9% | 9.5% | Unlock |
Earnings
Latest Release
Apr 16, 2025
EPS / Forecast
1.37 / --
Revenue / Forecast
918.80M / 807.84M
People Also Watch
FAQ
What Is the Ipsen SA (IPN) Stock Price Today?
The Ipsen SA stock price today is 100.70
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Vienna Stock Exchange stock exchange.
What Is the Stock Symbol for Ipsen SA?
The stock symbol for Ipsen SA is "IPN."
Does Ipsen SA Pay Dividends? What’s The Current Dividend Yield?
The Ipsen SA dividend yield is 1.39%.
What Is the Ipsen SA Market Cap?
As of today, Ipsen SA market cap is 8.39B.
What Is Ipsen SA's Earnings Per Share (TTM)?
The Ipsen SA EPS (TTM) is 4.30.
When Is the Next Ipsen SA Earnings Date?
Ipsen SA will release its next earnings report on Jul 31, 2025.
From a Technical Analysis Perspective, Is IPN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Ipsen SA Stock Split?
Ipsen SA has split 0 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.